Vicore Pharma Holding AB (6Y4) Stock Price & Analysis
6Y4 Stock Chart & Stats
- Day’s Range
- EUR 0.89 - EUR 0.89
- 52-Week Range
- EUR 0.77 - EUR 1.86
- Previous Close
- EUR 0.86
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 248.11M
- Enterprise Value
- EUR 2.64B
- Total Cash (Recent Filing)
- EUR 905.64M
- Total Debt (Recent Filing)
- EUR 0
- Price to Earnings (P/E)
- ―
- Beta
- 0.93
- Next Earnings
- Nov 05, 2026 (Est.)
- EPS Estimate
- -0.05
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance Sheet
Effectively no debt reduces solvency and refinancing risk while preserving financial flexibility for clinical development. The sizable equity base provides a buffer against near-term obligations, although continued losses could still erode that cushion and require future capital.
Focused Clinical Pipeline
Concentration on severe lung diseases gives Vicore a clear therapeutic focus and allows resources to be directed toward a lead asset rather than a broad, unfocused portfolio. Progress in C21 could therefore materially influence the company’s future development and partnering prospects.
Recent Revenue Growth
The reported TTM revenue increase indicates some recent improvement in reported income despite Vicore remaining at a very small revenue base. If sustained and followed by meaningful scaling, this growth could provide a foundation for reducing dependence on external funding over time.
Bears Say
Very Large Net Losses
The scale of ongoing net losses shows that Vicore has not yet reached an economically sustainable operating model. Persistent losses consume the equity base, constrain investment choices, and make future profitability dependent on successful development, commercialization, or additional financing.
Heavy Cash Burn
Deeply negative operating and free cash flow means clinical development currently requires substantial external funding. Continued deterioration in free cash flow increases the likelihood of additional equity issuance or other financing, which can dilute existing holders and limit strategic flexibility.
Limited And Volatile Revenue
Revenue remains too small to offset Vicore’s development costs and has shown meaningful annual volatility. This leaves the company dependent on advancing pipeline assets rather than established commercial sales, so revenue visibility and operating leverage remain weak over the medium term.
6Y4 FAQ
What was Vicore Pharma Holding AB’s price range in the past 12 months?
What is Vicore Pharma Holding AB’s market cap?
When is Vicore Pharma Holding AB’s upcoming earnings report date?
How were Vicore Pharma Holding AB’s earnings last quarter?
Is Vicore Pharma Holding AB overvalued?
Does Vicore Pharma Holding AB pay dividends?
What is Vicore Pharma Holding AB’s EPS estimate?
How many shares outstanding does Vicore Pharma Holding AB have?
What happened to Vicore Pharma Holding AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Vicore Pharma Holding AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Vicore Pharma Holding AB
Vicore Pharma Holding AB (publ), a Gothenburg, Sweden-based company, specializes in the discovery and advancement of therapies for rare lung conditions. Its core pipeline features VP01, an orally administered small molecule currently in Phase II clinical trials for indications such as interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19. The company is also progressing VP02, a novel formulation and delivery approach for an established immunomodulatory compound, which is in preclinical development for treating IPF. Vicore maintains strategic alliances, including a development cooperation with Emeriti Bio AB, a licensing arrangement with Nanologica AB (publ), and a collaboration with Alex Therapeutics AB focused on creating and clinically validating a digital therapeutic (DTx) built on the Alex DTx platform. Established in 2000, the company was formerly known as Mintage Scientific AB.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ahmed S. Mousa
- Employees
- 46
- Website
- www.vicorepharma.com
- Address
- Kronhusgatan 11, Stockholm, AB, 111 27, SE
Vicore Pharma Holding AB (6Y4) Earnings & Revenues
6Y4 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 11 | 2 | 9 |
| Technical Analysis | 3 | 2 | 5 |
| Moving Averages | 8 | 0 | 4 |